BIOPORTO

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers - tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company's tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem... BioPorto offers a range of leading, highly reproducible ELISA kits that are easy to use, including the CE marked human ELISA Kit for nephrotoxicity... BioPorto's flagship product, The NGAL Test™, aids in the risk assessment of AKI in critically ill patients. CE marked for IVD use in select regions.

Also known as: BioPorto A/S, BioPorto Diagnostics Inc.

VAT numbers: DK-18 64 58 82, DK: 18 64 58 82

Primary location: Hellerup Denmark